ViiV Healthcare Launches New HIV Therapy Cabenuva
… ViiV Healthcare Launches New HIV Therapy Cabenuva …

ViiV Healthcare Unveils New HIV Therapies Cabenuva and Vocabria

GlaxoSmithKline, Pfizer and Shionogi enterprise continues to advance its HIV-focused business mission and develop breakthrough treatments

John G. Baresky

ViiV’s advanced clinical research and product development efforts pay off with the creation of the unique Cabenuva tandem therapy

Available by prescription only, Cabenuva is administered as two intramuscular injections (cabotegravir and rilpivirine). The complete regimen combines the integrase strand transfer inhibitor (INSTI) cabotegravir, developed by ViiV Healthcare, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Janssen Sciences Ireland UC, one of the Janssen business units of Johnson & Johnson (NYSE: JNJ).

  • 600MG/3ML; 900MG/3ML suspension, extended-release (intramuscular)

ViiV has been tasked with a challenging mission since it was started

Founded in 2009, ViiV was founded by Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) combining their HIV business franchises. Shionogi (OTCMKTS: SGIOY) followed suit and transferred their HIV clinical and commercial assets to the ViiV organization in 2012. The ownership stakes are as follow:

  • 13.5% Pfizer
  • 10% Shionogi
  • Combivir (lamivudine and zidovudin)
  • Dovato (dolutegravir and lamivudine)
  • Epivir (lamivudine)
  • Epzicom (abacavir and lamivudine)
  • Juluca (dolutegravir and rilpivirine)
  • Lexiva (fosamprenavir calcium)
  • Retrovir (zidovudine)
  • Rukobia (fostemsavir)
  • Selzentry (maraviroc)
  • Tivicay/ Tivicay PD (dolutegravir)
  • Triumeq (abacavir, dolutegravir, lamivudine)
  • Trizivir (abacavir, lamivudine, zidovudine)
  • Viracept (nelfinavir mesylate)
  • Vocabria (cabotegravir)
  • Ziagen (abacavir)

Market access strategy is a pivotal priority of ViiV’s mission

In addition to creating complex therapies, market access strategy is a built-in element of ViiV’s commercial operations. Prescribing protocols, clinical complexity and cost of HIV/AIDs therapies inhibit the ability of medical professionals to easily prescribe these medications; these also hamper the efforts of patients to receive treatment and pay for it.

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/